Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO

Jasper Therapeutics (JSPR) announced that its Board of Directors has appointed Jeet Mahal as President and CEO, and a member of the Board, effective January 5. Mahal succeeds Ronald Martell, who is stepping down after joining the company as CEO in 2022. In addition, Thomas Wiggans, the current Chairperson of company’s Board of Directors, was appointed as the company’s Executive Chairperson. Mahal brings over thirty years of experience in the life sciences industry, including more than six years at Jasper where he has held roles as Chief Business and Financial Officer, and most recently as the COO. Mahal previously held senior leadership roles in business development, commercial and operating roles at Portola Pharmaceuticals, Johnson and Johnson and COR Therapeutics, and has led or contributed to development and/or strategic partnerships for a number of approved therapeutics, including Andexxa, Bevyxxa, and Xarelto.